Lupin Limited Press Release Sep 28 2026
Filed with NSE · · 3 pages · English
Earlier from Lupin
- Lupin Receives U.S. FDA Approval for Modafinil Tablets, USP
- Lupin and Tenpoint Therapeutics Announce Strategic Partnership to Commercialize YUVEZZI™ in the European Union, the United Kingdom, Switzerland, Norway, and Iceland
- Lupin Announces Approval from U.S. FDA for Pitolisant Tablets
- Lupin Limited Press Release Aug 17 2026
- Lupin Limited Press Release Aug 10 2026
Later from Lupin
- Lupin Receives Tentative Approval from U.S. FDA for Novel Apixaban Oral Suspension
- Lupin Limited has informed the Exchange regarding a press release dated October 06, 2026, titled "Lupin Launches Formoflo-G® MDI, World s First Fixed-dose Triple Combination Drug for COPD Management".
- Lupin Limited has informed the Exchange regarding a press release dated October 08, 2026, titled "Lupin Receives U.S. FDA Approval for Phytonadione Injectable Emulsion, USP".
- Lupin Limited has informed the Exchange regarding a press release dated October 23, 2026, titled "Lupin Appoints Brian Savage as President, Chief Legal Officer".
- Lupin Limited has informed the Exchange regarding a press release dated November 02, 2026, titled "Lupin Receives U.S. FDA Approval for Amifampridine Tablets".
Follow Lupin into a list and get an email when it puts out news.
Follow Lupin